Navigation Links
Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
Date:12/19/2007

FDA Offers Special Protocol Assessment for Reviroc

AMSTERDAM, December 19 /PRNewswire/ -- Kiadis Pharma announced today that it has successfully completed an End of Phase II meeting for Reviroc with the U.S. Food and Drug Administration (FDA). Reviroc is under development for elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The FDA agreed that the data from the completed phase II clinical Reviroc trial is sufficient to support the start of a phase III study. The FDA offered Kiadis Pharma its Special Protocol Assessment (SPA) procedure allowing Kiadis Pharma to work directly with the FDA to optimize the clinical design of the trial.

The FDA meeting followed the successful completion of a multi centre phase II study for Reviroc showing an improved overall survival after autologous bone marrow transplantation in Non-Hodgkin's lymphoma patients. The phase III clinical trial design for Reviroc will focus on patients with Large B cell lymphoma. Kiadis Pharma anticipates filing of the IND, SPA request and Orphan Drug Designation application with the FDA within the next few weeks.

"We are very pleased with the outcome of the End of Phase II meeting with the FDA and with the possibility to access the FDA's Special Protocol Assessment program. Together with the strong support by our principal investigators we are well prepared to design a clear path towards marketing authorization for Reviroc," said Manja Bouman, CEO Kiadis Pharma.

About Reviroc

Reviroc is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone-marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone mar
'/>"/>

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... SAN DIEGO , March 26, 2015  BioNano ... the appointment of  Terry Salyer as chief commercial ... building highly effective, worldwide sales teams in life sciences. ... Irys ® System, a genome-mapping platform to assemble ... and investigate structural variations. To date, 32 institutions located ...
(Date:3/26/2015)... March 26, 2015 PAREXEL International ... clinical research organization , announced today ... agreement to acquire all of the business ... leading provider of specialized pharmacovigilance services, based ... collection, detection, assessment, monitoring, and prevention of ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, ... at Align Technology, on “ Conducting Postmarket Registries - ... Global Conference and Exhibition on April 25th through April ... the poster presentation, Ale Gicqueau and Victor Chen will ... Registry, the requirements and resources to conduct the registry, ...
(Date:3/25/2015)... 2015 Agnition announced today that it ... Farmer, airing for the first time at 7:30 a.m. ... Farmer will explore the extremely important role soil microbes ... a patented Microbial Catalyst™ technology that enhances soil and ... segment will air again on April 28. , A ...
Breaking Biology Technology:BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2
... L.P., a subsidiary of Mylan Inc. (Nasdaq: ... market and distribute EMSAM(R) in the U.S. EMSAM, a ... which was approved by the U.S. Food and Drug ... depressive disorder. EMSAM previously was marketed and distributed by ...
... digital templating solution from Orthocrat. Using TraumaCad, UPMC Mercy,s ... within the UPMC enterprise. , ... ... today that UPMC Mercy, part of the UPMC global health ...
... 28 Cytopia Limited (ASX: CYT) announced that it will present ... CYT997, at the Annual Meeting of the American Society of Clinical ... clinical investigators for the program, will be presenting the poster in ... Therapeutics - Vascula ...
Cached Biology Technology:Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder 2Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy 2Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy 3Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO 2
(Date:3/11/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has ... by Product, Application & By Geography - Global Forecast ... , This report predicts that the access ... 2020, with an estimated CAGR of 10.6%. ... such as contact cards & readers, contactless cards & ...
(Date:3/10/2015)... 2015 Transforming How We Look ... Medicine in Human Space Flight" by Michael ... , Ph.D. was recently featured by Springer Science Media, highlighting ... Specifically, "Personalized Medicine in Human Space Flight" ... in 2013 and 2014 from Springer in the journal ...
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... at an alarming rate compared with other species, according to ... The rate of extinctions increased noticeably after 1950, although ... of extinct species has grown by 25 percent since 1989. ... US Geological Survey, examines North American freshwater fish extinctions from ...
... 2012 Scientists already know that the tiny hairs on ... vertical surfaces. Now, University of Akron researchers are unfolding clues ... to create a synthetic adhesive that sticks when moist or ... the sole of a gecko toe, and the pad repels ...
... along the ground by alternately squeezing and stretching muscles ... each wave of contractions. Snails and sea cucumbers also ... our own gastrointestinal tracts operate by a similar action, ... the stomach. Now researchers at MIT, Harvard University ...
Cached Biology News:Gecko feet hold clues to creating bandages that stick when wet 2Soft autonomous robot inches along like an earthworm 2Soft autonomous robot inches along like an earthworm 3
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Biology Products: